This inventor holds 1 USPTO granted patent. Top assignee: Pharmatarget, Inc.. Active years: 1997.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1997
Title: The Innovative Contributions of Stan Obino
Introduction
Stan Obino is a notable inventor based in Edina, MN (US). He has made significant strides in the field of medical technology, particularly in the treatment of cardiac arrhythmia. His innovative approach has led to the development of a unique device that aims to improve patient outcomes.
Latest Patents
Stan Obino holds a patent for a device and method for the treatment of cardiac arrhythmia. This patent describes an implantable programmable drug delivery system designed for the injection of a pharmaceutical agent into the peritoneum. The device consists of three main components: a main body containing electronics, a power supply, valve means, and a drug reservoir; an electronic lead that transmits impulses from the heart and delivers electronic responses; and a specialized drug delivery catheter for administering agents to the peritoneal cavity or near the exterior of the pericardium. He has 1 patent to his name.
Career Highlights
Stan Obino is currently employed at Pharmatarget, Inc., where he continues to work on innovative solutions in the medical field. His contributions have been instrumental in advancing technologies that address critical health issues.
Collaborations
Some of his notable coworkers include Paul J Buscemi and Brian Jackson. Their collaborative efforts contribute to the innovative environment at Pharmatarget, Inc.
Conclusion
Stan Obino's work exemplifies the spirit of innovation in medical technology. His patent for a device aimed at treating cardiac arrhythmia showcases his commitment to improving healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile